According to Ernst & Young’s Progressions 2011 report, in the world of Pharma 3.0, success will be based not on how many drug units are sold, but on how well pharma’s market offerings improve health outcomes, putting patients and payers at the center of the model.
As part of this transition, pharma companies are embracing a role that goes far beyond developing and manufacturing products, dramatically increasing their investments in new and innovative offerings to meet the demands of a patient-empowered, data-driven, outcomes-focused future…
Top 10 Advertising Categories (Jan-Sep 2010 vs. Jan-Sep 2009)
Key Digital Media Trends to Watch for 2010
David Brennan. Executive Director and CEO, AstraZeneca, a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development, and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious disease. For more information, visit astrazeneca.com.
Deirdre Connelly. President, North America Pharmaceuticals, GlaxoSmithKline, one of the world’s leading research-based pharmaceutical and healthcare companies. For more information, visit gsk.com.
Monique Levy. VP of Research, Manhattan Research, a global healthcare market research and advisory firm focused on the digital trends shaping the future of consumer and physician marketing. For more information, visit manhattanresearch.com.
Carolyn Buck Luce. Global Pharmaceutical Leader, Ernst & Young, a global provider of assurance, tax, transaction, and advisory services. For more information, visit ey.com.